PF-Atlas › Clinical Trials › NCT04512170

Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC585 in Healthy Male and Female Subjects

HEC585 · Phase 1

Registry ID
NCT04512170
Phase
Phase 1
Status
Completed
Drug / intervention
HEC585
Sponsor
Sunshine Lake Pharma Co., Ltd.
Start
2020-07-13

About this trial

HEC585 is evaluated in NCT04512170, a Phase 1 idiopathic pulmonary fibrosis study sponsored by Sunshine Lake Pharma Co., Ltd.. Current status: Completed.

View NCT04512170 on ClinicalTrials.gov →

Explore related

All HEC585 trialsAll IPF trials

Related trials

HEC585 — NCT03092102HEC585 — NCT05060822HEC585 — NCT05383131
Medical disclaimer. This page summarizes public trial data for NCT04512170 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.